Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP...

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Immune checkpoint inhibitors targeting PD-1/PD-L1 interactions show promise in cancer therapy.
• Colorectal cancers (CRCs) exhibit poor response to current immune-checkpoint therapies, necessitating novel approaches.
• Simvastatin, a cholesterol biosynthesis inhibitor, has unknown roles in immune checkpoint regulation and cancer immunoregulation.

Purpose of the Study:

• To investigate the potential of simvastatin as an immunotherapy for colorectal cancer.
• To elucidate the mechanism by which simvastatin affects immune checkpoints and long noncoding RNA (lncRNA) regulation in CRC.
• To explore the role of lncRNA SNHG29 and YAP in simvastatin-mediated anti-tumor immunity.

Main Methods:

• Investigated simvastatin's effect on PD-L1 expression and anti-tumor immunity.
• Analyzed the role of lncRNA SNHG29 in regulating PD-L1 expression.
• Examined the interaction between SNHG29, YAP, and PD-L1.
• Utilized patient-derived tumor xenograft (PDX) models and clinicopathological analysis in CRC samples.

Main Results:

• Simvastatin inhibited PD-L1 expression and promoted anti-tumor immunity by suppressing lncRNA SNHG29.
• SNHG29 interacted with YAP, inhibiting its degradation and facilitating PD-L1 transcriptional downregulation.
• The lncRNA SNHG29-mediated PD-L1 signaling axis was confirmed to reprogram the tumor microenvironment in CRC models and patient samples.

Conclusions:

• Simvastatin demonstrates potential as a therapeutic agent for colorectal cancer immunotherapy.
• Simvastatin suppresses lncRNA SNHG29-mediated YAP activation, leading to reduced PD-L1 expression.
• This mechanism promotes anti-tumor immunity, offering a new strategy for CRC treatment.